RT Journal Article SR Electronic T1 Systemic markers of inflammation in stable bronchiectasis JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 820 OP 824 DO 10.1183/09031936.98.12040820 VO 12 IS 4 A1 Wilson, CB A1 Jones, PW A1 O'Leary, CJ A1 Hansell, DM A1 Dowling, RB A1 Cole, PJ A1 Wilson, R YR 1998 UL https://publications.ersnet.org//content/12/4/820.abstract AB Patients with bronchiectasis have an active local and systemic inflammatory response during infective exacerbations. Systemic markers of inflammation were investigated during a stable phase of their illness, because continued inflammation could affect their general health and be involved in disease progression. The relationship between levels of various systemic markers of inflammation and extent of disease on computed tomographic scan, lung function, sputum bacteriology and health related quality of life (HRQoL) was investigated in 87 noncystic fibrosis bronchiectasis patients. Several markers were elevated and correlated with the extent of disease and poor lung function. The total white cell count, neutrophil count and erythrocyte sedimentation rate correlated with both disease measures. Sputum bacteriology did not correlate with inflammation markers and patients with positive and negative cultures were similar. C-reactive protein and total white cell count correlated with some components of a disease-specific HRQoL questionnaire. In conclusion, patients with bronchiectasis in a stable phase have raised systemic markers of inflammation. Some markers, particularly the neutrophil count, correlate with disease severity. This result is in keeping with the hypothesis that the level of inflammation determines disease progression and health status.